Key facts
- It has raised $300K; the latest was Later Stage VC in Oct 2025.
- Notable investors include US National Science Foundation, Portland Seed Fund, Oregon Bioscience Incubator, Small Business Innovation Research and Small Business Technology Transfer Programs, Westchester County Biosciences Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SurgiVance
- ·The full record, as it builds
Funding rounds
No funding rounds for SurgiVance are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SurgiVance
Manufacturer of medical devices intended for pathological image analysis and diagnosis. The company develops a microscope for direct-to-digital imaging of fresh tissue biopsies, speeding pathological image analysis, and diagnosis at the point of care, a digital diagnostic imaging platform that acts as a diagnostic tool for the analysis of digital pathology images and has features to analyze surgically removed tissue specimens and histopathology specimens, enabling clinicians to bring fast diagnosis to the point of care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 3
- Website
- surgivance.com/
- Ownership
- Privately Held (backing)
SurgiVance doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SurgiVance shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SurgiVance in its N-PORT filings yet. We sweep new filings monthly.